Leukocyte count and risk of thrombosis in patients undergoing haematopoietic stem cell transplantation or intensive chemotherapy

Thrombosis and Haemostasis

Volumn 103, Issue 6, 2010, Pages 1228-1232

  Stoffel, Nadina ^a   Rysler, Christine ^a   Buser, Andreas ^a   Gratwohl, Alois ^a   Tsakiris, Dimitrios A ^a   Stern, Martin ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Chemotherapy; Leukocytes; Stem cell transplantation; Thrombosis

Indexed keywords

ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CENTRAL VENOUS CATHETER; COHORT ANALYSIS; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; FEMALE; HAZARD RATIO; HUMAN; HUMAN TISSUE; LEUKOCYTE COUNT; LEUKOCYTOSIS; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; OVARIAN VEIN; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; STROKE; THROMBOEMBOLISM; ADOLESCENT; ADVERSE DRUG REACTION; CELL COUNT; CENTRAL VENOUS CATHETERIZATION; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY; LYMPHOCYTE DEPLETION; METABOLISM; MIDDLE AGED; MONONUCLEAR CELL; PATHOLOGY; POSTOPERATIVE COMPLICATION; THROMBOSIS;

C REACTIVE PROTEIN;

ADOLESCENT; ADULT; AGED; C-REACTIVE PROTEIN; CATHETERIZATION, CENTRAL VENOUS; CELL COUNT; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY; HUMANS; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE DEPLETION; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; RETROSPECTIVE STUDIES; RISK FACTORS; THROMBOSIS;

EID: 77953158638     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH09-10-0700     Document Type: Article

References (18)

1. Barbui T, Carobbio A, Rambaldi A, et al. Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor? Blood 2009; 114: 759-763.
2. Carobbio A, Antonioli E, Guglielmelli P, et al. Leukocytosis and risk stratification assessment in essential thrombocythemia. J Clin Oncol 2008; 26: 2732-2736.
3. Passamonti F, Rumi E, Pascutto C, et al. Increase of leukocyte count over time predicts thrombosis in patients with low risk essential thrombocythemia. J Thromb Haemost 2009; 7: 1587-1589..
4. Landolfi R, Di Gennaro L, Barbui T, et al. Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. Blood 2007; 109: 2446-2452.
5. Coller BS. Leukocytosis and ischemic vascular disease morbidity and mortality: is it time to intervene? Arterioscler Thromb Vasc Biol 2005; 25: 658-670.
6. Khorana AA, Kuderer NM, Culakova E, et al. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008; 111: 4902-4907.
7. Khorana AA, Francis CW, Culakova E, et al. Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncol 2006; 24: 484-490.
8. Pihusch R, Salat C, Schmidt E, et al. Hemostatic complications in bone marrow transplantation: a retrospective analysis of 447 patients. Transplantation 2002; 74: 1303-1309. (Pubitemid 35402602)
9. Jones RJ, Lee KS, Beschorner WE, et al. Venoocclusive disease of the liver following bone marrow transplantation. Transplantation 1987; 44: 778-783. (Pubitemid 18034278)
10. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974; 18: 295-304.
11. Kuter DJ. Thrombotic complications of central venous catheters in cancer patients. Oncologist 2004; 9: 207-216.
12. Falanga A, Marchetti M, Vignoli A, et al. Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera. Exp Hematol 2005; 33: 523-530.
13. Kostelijk EH, Fijnheer R, Nieuwenhuis HK, et al. Soluble P-selectin as parameter for platelet activation during storage. Thromb Haemost 1996; 76: 1086-1089. (Pubitemid 27013653)
14. Ridker PM, Hennekens CH, Buring JE, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342: 836-843.
15. Devaraj S, Singh U, Jialal I. The evolving role of C-reactive protein in atherothrombosis. Clin Chem 2009; 55: 229-238.
16. Gonsalves A, Carrier M, Wells PS, et al. Incidence of symptomatic venous thromboembolism following hematopoietic stem cell transplantation. J Thromb Haemost 2008; 6: 1468-1473.
17. Gerber DE, Segal JB, Levy MY, et al. The incidence of and risk factors for venous thromboembolism (VTE) and bleeding among 1514 patients undergoing hematopoietic stem cell transplantation: implications for VTE prevention. Blood 2008; 112: 504-510.
18. Monreal M, Zacharski L, Jimenez JA, et al. Fixed-dose low-molecular-weight heparin for secondary prevention of venous thromboembolism in patients with disseminated cancer: a prospective cohort study. J Thromb Haemost 2004; 2: 1311-1315.